Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model

• Main Authors: Laurie Freire Boullosa (Author), Jinthe Van Loenhout (Author), Christophe Hermans (Author), Ho Wa Lau (Author), Céline Merlin (Author), Elly Marcq (Author), Farnaz Sedigheh Takhsha (Author), Wim Martinet (Author), Guido R. Y. De Meyer (Author), Filip Lardon (Author), Evelien L. J. Smits (Author), Christophe Deben (Author)
• Format: Book
• Published: MDPI AG, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has already been investigated in various cancer mouse models as a single drug, or in combination with other molecules. However, there are inconsistencies in the literature on the solvent, dose and administra...